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Purpose. To investigate angiogenesis, multiple drug resistance (MDR) and proliferative activity as prognostic variables in patients
suﬀering from osteosarcoma. Methods. Histologic biopsies from 117 patients treated in the period from 1972 through 1999 were
immunohistologically investigated regarding angiogenesis (CD34), proliferative activity (MIB-1), and the expression of p53 and
MDR (P-glycoprotein (Pgp); clones JSB-1, C494, and MRK16). Quantitative and semiquantitative scores of immunoreactive cells
were analyzed statistically along with retrospectively obtained clinicopathologic variables. Results. Chemotherapy reduced the rate
of amputations (P = .00002). The Pgp was overexpressed (score ≥2) in 48% of the primary, diagnostic biopsies, and high Pgp
correlated with high Pgp in postsurgical specimens (P = .003). In contrast, no such associations were disclosed for estimates of
angiogenesis (P = .64) and p53 (P>. 32), whereas the MIB-1 index was reduced in the post-chemotherapy specimens (P = .02).
The overall, disease-speciﬁc survival was 47%, increasing to 54% in patients receiving pre-operative chemotherapy. Statistical
analyses showed prognostic impact exclusively by patient age and type of osteosarcoma. Discussion. The studied series of patients
documented already prior to the chemotherapy era, a rather excellent survival and estimates of angiogenesis, proliferation, p53,
and Pgp expressions, did not demonstrate suﬃcient power to serve as predictors of treatment response or survival.
Copyright © 2008 Flemming Brandt Sorensen et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
The treatment of patients with osteosarcomas has during the
last two decades changed from a solely surgical approach
to a highly complex multimodal therapy with preoperative
chemotherapy as the dominating innovation. Prior to the
chemotherapy era, the studies addressing survival of patients
with osteosarcoma have, among others, identiﬁed morpho-
logicaltypeoftumor ,siteoftumor ,tumorstageandsize,and
duration of symptoms as prognostic variables of relevance
[1, 2]. Investigations including large patient populations
treated after the introduction of preoperative chemotherapy
protocols have evidenced a shift toward histological response
to chemotherapy as the most informative prognostic param-
eter [3–5], a conclusive ﬁnding also corroborated by meta-
analysis [6] and large-scale studies [7].
Although the treatment outcome for patients with
osteosarcoma has improved signiﬁcantly regarding survival
after the introduction of preoperative chemotherapy, it is
still diﬃcult to optimize the therapy oﬀered to the individual
patient in that the most important prognostic variable can-
not be evaluated precisely until after surgical intervention.
The extent of tumor necrosis can be guided by various
image scans, but ﬁrst after completion of preoperative2 Sarcoma
chemotherapy, objective measures in the histopathological
examination of the surgical specimen are able to estimate the
true extent of chemotherapy-induced tumor necrosis [8, 9].
Attempting to get around this obstacle, researchers have
focused their investigations on the characteristics of the pri-
mary, diagnostic biopsy from patients with osteosarcomas.
Features like proliferation rate [10], P53 gene alteration [11],
and especially, multiple drug resistance (MDR) [12]h a v e
beenexamined.Findingsregardingpredictionofchemother-
apeutically induced tumor necrosis have, however, been
rather contradicting, and thus diﬃcult to implement in
a routine diagnostic setting of osteosarcoma. Moreover,
recent results from a randomized phase III trial of the
European Osteosarcoma Intergroup suggest that intensiﬁed
chemotherapy may improve histologic response but not
survival in osteosarcoma patients [13]. This questions the
idea of using the extent of chemotherapeutically induced
osteosarcoma necrosis as a surrogate measure of clinical
outcome.
The development of new microvessels in tumors, the so-
called neoangiogenesis, has for some years been investigated
in a number of diﬀerent types of neoplasms, and has
indeed been shown to be of prognostic signiﬁcance in
some. Estimating the level of angiogenesis in a malignant
neoplasm is attractive for several reasons, and may reﬂect the
capacity for a malignant tumor to metastasize, and from the
therapeutic point of view, for developing antiangiogenetic
drugs that may lead to starvation and ultimately death of
the tumor in question. The angiogenetic level may also be of
interest in planning systemic chemotherapy, as it is the case
for patients with osteosarcomas, and it has accordingly also
been investigated in such neoplasms [14–18].
In this retrospective study, we have investigated the
prognostic value of angiogenesis, proliferation rate, alter-
ations in p53 and MDR/P-glycoprotein (Pgp) expressions in
osteosarcomas from patients treated at the Sarcoma Center,
Aarhus University Hospital, Denmark from 1972 through
1999, using an immunohistochemical approach. The study
thus includes patients treated both before and after the
introduction of preoperative chemotherapy, and provides an
updateofthetreatmentresultsinpatientswithosteosarcoma
at Aarhus University Hospital.
2. PATIENTS
The cohort of patients studied was retrospectively retrieved
from the ﬁles of the University Institute of Pathology, Aarhus
University Hospital, Denmark in the period from 1972
through 1999. This database was combined with the clinical
database at the Department of Oncology, Aarhus University
Hospital,Denmark,andatotalof134consecutivelyadmitted
patients treated for primary, nonmetastatic osteosarcoma
of the extremities and pelvis were identiﬁed. Most of
the patients had been referred to the Sarcoma Center of
Aarhus University Hospital. Retrieval of clinical follow-up
information and/or histological material was unsuccessful in
17 cases, leaving a total of 117 patients for inclusion into the
investigation with at least 5 years of follow-up after primary
treatment.
Table 1: Clinicopathological data of 117 patients with primary
osteosarcoma.
N
Sex
Women 41
Men 76
Age
Mean (years) 23.8
SD (years) 16.6
Range (years) 4–74
Tumor site
Humerus and radius 12
Pelvis 10
Femur 66
Tibia 21
Fibula 6
Tarsal bones 2
Extent of tumor
Intraosseous 6
+ Cortical breakthrough 16
+ Soft tissue extension 95
Type of osteosarcoma
Classical high grade 98
Other types 19
Largest tumor diametera
Mean (cm) 10.1
SD (cm) 3.9
Range (cm) 3–20
Diagnostic delayb
Mean (months) 5.3
SD (months) 3.9
Range (months) 1–36
Type of surgical treatment
None 5
Tumor resection 26
Amputation 86
Histological radicality of surgeryc
Intralesional resection 4
Marginal resection 5
Wide resection (radical) 49
Amputation (radical) 54
Chemotherapyd
+ Preoperative chemotherapy 46
− Preoperative chemotherapy 63
+ Other kind of chemotherapy 8
Radiation therapye
+ Radiation therapy 7
− Radiation therapy 110
Clinical response to primary treatment
Complete clinical response 107
Persistent disease 10Flemming Brandt Sorensen et al. 3
Table 1: Continued.
N
Histological response to preoperative chemotherapy
100% tumor necrosis 6
>90% tumor necrosis 11
50–90% tumor necrosis 14
<50% tumor necrosis 10
No necrosis 5
Recurrent diseasef
No recurrence 51
+ Recurrence 56
Persistent disease 10
Survival statusg
Survivors 58
Death caused by OS 58
Death from unrelated disease 1
aTumer diameter not known for 3 patients.
bDiagnostic delay was estimated from the anamnestic informations given in
the clinical records and was unknown for 19 patients.
cFive patients did not receive surgical treatment, but were by own wish
treatedbyeitherchemotherapyand/orradiationtherapyalone/combinedor
refused any treatment.
dOne patient received chemotherapy as the only treatment modality and
did not wish the subsequent surgery, whereas 7 other patients received
chemotherapy as adjuvant to other treatment.
eTwo patients received radiation therapy as the only treatment.
fRecurrence status at the closure of the study.
gSurvival status at the closure of the study.
The clinicopathological data of the studied patients are
summarized in Table 1. Prior to 1984, the treatment of
osteosarcoma at the Sarcoma Center, Aarhus University
Hospital was limited to surgery, but after 1984, preoperative
chemotherapywasoﬀeredtoallpatients,followedbysurgical
treatment which has increasingly focused on limb-salvage
resections. In the early chemotherapy era, the MAP-regimen
(mitomycin, adriamycin, and cisplatin) [19]w a su s e d ,b a s e d
on Mayo Clinic experience. From 1991, the chemotherapy
was changed to the European Osteosarcoma Intergroup Study
approach, based on doxorubicin and cisplatin [13]. A few
patients received chemotherapy and/or radiation therapy
alone or in combination (Table 1), mostly as an adjuvant
postoperative therapy at recurrent disease, in that only very
few patients refused surgery at primary treatment.
Theclinicaldatawereretrievedfromthemedicalrecords.
Patients were seen at regular intervals as outpatients at
the Department of Oncology, Aarhus University Hospital,
or at admission to this Department or the Department of
Orthopaedic Surgery in the case of recurrence. Thus, any
type of recurrence was added to the clinical records and to
the clinical database, and in the case of death, the cause of
deathwasestablishedfromautopsyrecordsorfromthedeath
certiﬁcates. The investigation was approved by the Ethical
Committee of Aarhus County (Project no. 1999/4601) and
by the Danish Data Registration Authorities (Danish Data
Protection Agency, Project no. 2000-41-0174).
3. MATERIAL AND METHODS
Primary, diagnostic tumor biopsies, formalin ﬁxed, and
paraﬃn embedded, from all 117 patients and tumor speci-
mens from the 112 patients, who underwent surgical treat-
ment, were available for investigation. One representative
tissue block was selected from each case by screening all
histological sections. In this way, 117 tissue blocks from
primary, diagnostic biopsies, and 46 tissue blocks from sur-
gical resection specimens of patients receiving preoperative
chemotherapy were selected for the investigation. When
possible, the tissue blocks were selected from the soft tissue
extensions of the osteosarcomas, in that this tissue had
underwent none or only a short period of decalciﬁcation in
either nitric acid or EDTA.
The surgical specimens from patients treated with
preoperative chemotherapy had been processed according
to international guidelines of estimating the extent of
chemotherapy-induced tumor necrosis [8, 9]. Brieﬂy, the
resected osteosarcoma was sawed along the largest diameter
of the tumor, and a slice of the surgical specimen was
subsequently decalciﬁed and embedded in paraﬃn blocks
in toto. All histological sections cut from each tissue block
were examined and a semiquantitative estimate of overall
tumorcellnecrosisinpercentwasreported.Thetissueblocks
used for further studies were carefully selected to ensure vital
tumor tissue, but in 6 cases with 100% tumor necrosis, no
further investigations were performed.
3.1. Immunohistochemistry
Histologically, 4μm thick sections were cut from each tissue
block, placed on coated slides, and deparaﬃnized in xylene
followed by ethanol. Endogenous peroxidase was blocked
in methanol with H2O2 (v/v 35%). Several experiments
were carried out to unmask epitopes, including various
enzymatic treatments and buﬀer baths in micro-oven, but
the fragile, decalciﬁed tissue sections mostly detached from
the histologic slides. The best results were obtained by
immersing the histologic slides in TEG buﬀer (pH 9.0)
at 60◦C in a heating cupboard for 72 hours, followed by
sensibilization in TRIS buﬀer (pH 7.6) and normal horse
serum (DAKO, Glostrup, Denmark).
Incubation with primary antibodies for detecting pro-
liferation (clone MIB-1, DAKO, Glostrup, Denmark), p53
(clone DO-7, DAKO, Glostrup, Denmark), and CD34 (clone
QBend10, Immunotech, Quebec, Canada), diluted 1 : 200,
1 : 200, and 1 : 100, respectively, in antibody diluent (DAKO,
Glostrup, Denmark) was performed overnight (18 hours),
followed by rinsing in TRIS buﬀer. Secondary biotinylated
antibody (PK-6200, Vector) was added for 1 hour, followed
by TRIS buﬀer added 0.5% blocking reagent (DuPont TSA
Kit). To intensify the staining, the histologic sections were
treated with tyramide (in TRIS buﬀer added H2O2)a n d
rinsed in TRIS buﬀer. Avidin-biotin complex served as the
tertiary antibody (PK-6200, Vector), with incubation for 1
hour followed by rinsing in TRIS buﬀer. Diaminobenzidine
(DAB) was used as chromogen, and ﬁnally the histologic
sections were counter stained in Mayer’s hematoxyline and4 Sarcoma
Figure 1: Field of vision showing an osteosarcoma stained
immunohistochemically by MIB-1 to demonstrate cells in prolif-
eration cycle (brown nuclear stain). A counting frame has been
superimposed onto the histologic section for estimation of the
rate and index of neoplastic proliferation. Using an unbiased two-
dimensional counting rule, nuclei in focus inside the frame or
on the hatched, blue edges are counted, as long as they do not
intersect with the fully drawn, red exclusion edges of the frame or
their extensions. In this example, 6 nuclei in cycle (brown) and 10
“resting” nuclei (blue) are counted (original magniﬁcation: 400X).
cover slipped in Aquatex. The tyramide signal ampliﬁcation
(TSA) showed excellent results for staining with MIB-1 and
p53, whereas it had no improvement on the staining for
CD34, which was overall of rather poor quality with only 95
assessable biopsies out of a total of 163.
The immunohistological staining for MDR (Pgp) was
carried out by employing three diﬀerent monoclonal anti-
bodies, clones JSB-1, C494 (Zymed Laboratories Inc., Calif,
USA), and MRK16 (Alexis Biochemical, Lausen, Switzer-
land), diluted 1 : 20, 1 : 500, and 1 : 400, respectively.
Visualization was performed by the Envision technique
(DAKO, Glostrup, Denmark). Preliminary trials showed
rather diﬀerent staining results of individual biopsies with
the 3 diﬀerent antibodies, and accordingly it was decided to
perform the staining procedure of all cases with a primary
antibody cocktail containing all 3 clones, which has also
been recommended by an international consensus report
regarding detection of Pgp [20]. All immunohistochemical
procedures were followed by negative controls, omitting the
primary antibody. For MIB-1, p53, and CD34, the tumor
sections had an inborn positive control, and sections from
normal human kidney were used as positive control for the
Pgp staining.
There were no diﬀerences in the quality or scorability of
the immunohistochemical stains, when comparing osteosar-
comas included early or late in the nearly 30-year uptake
period of the study.
3.2. ScoringofMIB-1andp53
The immunoreactions for both MIB-1 and p53 are nuclear,
but a few cases showed in addition a weak, cytoplas-
mic reaction, which did not, however, interfere with the
morphometric quantiﬁcation of the sections, in that the
tyramide signal ampliﬁcation technique highly intensiﬁed
the nuclear staining. The quantiﬁcation of the MIB-1 and
p53 immunoreactivity was carried out, using the same mor-
phometric approach, applying the computer-assisted CAST-
grid system (Olympus, Denmark). At low magniﬁcation,
the histological sections were projected onto a computer
screen, using a video camera. The computer software enables
drawing around the tumor area (the so-called meander),
and within this area, the computer generates ﬁelds of
vision at high magniﬁcation (1425X), with the ﬁrst ﬁeld
generated at random, and the subsequent ﬁelds distributed
systematically within the meander area. A counting frame
was superimposed on the histological image, and using an
unbiased, two-dimensional counting rule [21], the positive
and negative nuclear proﬁles were counted (Figure 1). The
ratio of positive to negative nuclear proﬁles was calculated
in percent, and, moreover, the density index of positive
nuclear proﬁles pr. mm2 tumor area was calculated. On the
average, 50 ﬁelds of vision (range: 18–103) were investigated
in each tumor (corresponding to a mean tumor area of
about 80mm2), with a mean of 140 counted nuclear proﬁles
per case (range: 5–542). The sampling fraction within the
studied tumor sections ranged between 0.7% and 6.7%.
3.3. Estimationofangiogenesis
The histological sections were scanned at low magniﬁcation
to localize the three so-called hot spots with increased
microvascularity (Figure 2(a)). In each of these hot spots,
the neoangiogenesis within the tumor tissue was quantiﬁed
using the Chalkley technique [22], as recommended earlier
[23]. This method uses a graticule, mounted in the ocular
of the microscope, with 25 randomly distributed points.
At high magniﬁcation (250X), the ocular was rotated until
the highest number of these 25 points superimposed on
microvascular proﬁles in the tumor tissue (Figure 2(b)). The
mean of the three hot spot counts was reported as the
angiogenetic Chalkley number. In cases with no obvious hot
spots, the mean of three randomly selected ﬁelds of vision
within the tumor area represented the Chalkley number.
As mentioned above, the angiogenesis could not be scored
in a large number of cases because of a false negative
immunostain. This is probably caused by an inherent defect
in the studied tissue sections, may be due to acid exposure
during decalciﬁcation at the primary tissue processing, in
that a lot of microvascular proﬁles could be demonstrated
morphologically.
3.4. ScoringofMDR/Pgp
The scoring of Pgp immunostaining was carried out on
a semiquantitative scale, in accordance with earlier studies
performed at the Rizzoli Clinic, Italy [12]: score 0=complete
absence of immunoreactive tumor cells; 1=scattered, weakly
immunoreactive tumor cells in less than 10% of the histo-
logical specimen; 2=diﬀuse, weakly immunoreactive tumor
cells in more than 10% of the tumor area; 3=diﬀuse,
intense immunopositivity in more than 10% of the tumor
cells. A Pgp score ≥2 was considered to represent resistance
to chemotherapy [12, 17]. The heterogeneity of the PgpFlemming Brandt Sorensen et al. 5
(a) (b)
Figure 2: (a) Low-power view of a histologic section from an osteosarcoma, showing a microvascular hot spot in the lower left
corner (original magniﬁcation: 40X). (b) Histologic section with the Chalkley graticule superimposed. The graticule, equipped with
25 stochastically spaced points, is rotated until the highest number of these 25 points coincides with immunohistochemically stained
microvascular proﬁles in the tumor tissue. The mean of three hot spot counts is reported as the angiogenetic Chalkley number
(immunohistochemical stain by CD34 to highlight endothelial cells and vascular proﬁles; original magniﬁcation: 200X).
Figure 3: Histologic section of an osteosarcoma stained by a
“cocktail” of antibodies against P-glycoprotein (MDR). In this
case, the stain shows intense membranous accentuation with a
sparse cytoplasmic reaction (MDR score = 3; original magniﬁcation
200X).
immunostainwithinonetumorsection,andamongdiﬀerent
tumor sections, was only moderate, with just a few cases
showing marked variability in staining intensity, and the
scoring was based on the highest degree of immunoreactivity
within the examined histological slides. Mostly, the Pgp pos-
itive cells showed a diﬀuse cytoplasmic immunoreactivity,
but in some cases, an enhanced membrane staining was
visualized (Figure 3), as was reinforced immunoreactivity
of the Golgi region. Complete absence of Pgp-staining was
only recorded in 13 specimens, and in one specimen the
Pgp-reactivity could not be estimated because of recurrent
detachment of the histological section from the slide during
processing.
4. STATISTICS
Associations between categorical variables were assessed
by χ2-test or Fisher’s exact test. Student’s t-test was used
for comparison of continuous variables between groups of
patients. A rang sum test was used if the variation in the data
was poorly described by a normal distribution. A paired t-
test or McNemar’s test was used for pre versus post com-
parisons. Associations between continuous variables were
assessed by Pearson’s correlation coeﬃcient and Spearman’s
correlation coeﬃcient for nonnormal data.
Survival times and time to relapse were described by
Kaplan-Meier plots and the prognostic evaluation of the
variables was performed by log rank tests; the continuous
variables were dichotomized at the median. Patients were
followed until death from disease, or until the latest clinical
control at the closure of the study. A 5% level of signiﬁcance
was used for all statistical tests.
5. RESULTS
5.1. Clinicopathologicdata
The obtained clinicopathological data are summarized in
Table 1. Seventy one (61%) and 46 patients (39%) date from
the time before and after the introduction of preoperative
chemotherapy, respectively.
On the average, the diagnostic delay was estimated to
nearly half a year, but with a wide range, with 11 patients
having a delay for more than one year. This may explain the
fact that the vast majority of osteosarcomas evidenced soft
tissue extension at diagnosis, with only 19% of the patients
presenting with a tumor limited by cortical bone. Nineteen
tumors (16%) represented other types of osteosarcomas,
than the conventional high-grade neoplasm. This group of
patients showed a heterogeneous range of morphological
types, including both small cell and telangiectatic osteosar-
comas, and osteosarcomas of lower grade malignancy.
Five patients did not receive surgical treatment, whereas
26 patients underwent limb-salvage surgery in combina-
tion with preoperative chemotherapy. The majority of the
patients had amputation which represents a reﬂection of
secularity related to the retrospective design with patients6 Sarcoma
Table 2: Histological radicality of surgery in relation to preoperative chemotherapy coursea. P value
b = .00002.
Type of histological radicality of surgical specimen: Preoperative chemotherapy not given Preoperative chemotherapy given

Intralesional or marginal resection 5 4 9
Wide resection 19 30 49
Amputation 43 11 54

67 45 112
aFive patients did not receive surgical treatment, but were by own wish treated by either chemotherapy and/or radiation therapy alone/combined or refused
any treatment.
bχ2-test.
Table 3: Angiogenesis, tumor cell proliferation, and nuclear p53 expression in primary, diagnostic biopsies from osteosarcomas.
N Mean SD Range
Angiogenesisa 95 6.79 2.50 2.00–14.00
Proliferation rate (%) 117 50.6 18.8 5.1–90.2
Proliferation index (mm−2) 117 1990 1164 14–8388
p53 expression (%) 117 68.0 24.4 5.5–100.0
p53 index (mm−2) 117 2615 1437 15–10556
aIt was technically impossible to obtain evaluable immunohistochemical stains for CD34 in 12 cases.
treated within a period of 27 years. Although histological
evaluation of the surgical specimens showed intralesional
resection in 4 cases, the clinical response to treatment
was judged incomplete (persistent disease) in 10 patients.
However, the latter group includes also 5 patients, who did
not receive primary surgical treatment, whereas one patient
was found to have metastatic disease shortly after surgical
treatment.
In Table 2, the relationship between the type of surgical
treatment, documented by the histological examination of
the surgical specimen, and the administration chemotherapy
has been listed. There is a signiﬁcant shift from ampu-
tations to surgical treatment by wide resections with the
introduction of preoperative chemotherapy (P = .00002).
Only 35% of the patients receiving this treatment modality
had, however, excellent histologic response (>90% tumor
necrosis).
5.2. Quantitativevariables
Results regarding angiogenesis, proliferation, and p53 ex-
pression are summarized in Table 3. Separate analysis of
these variables in the group of nonconventional osteosar-
comas showed that these parameters, on the average, were
not statistically diﬀerent from the results harvested from
the investigated conventional osteosarcomas (.06 <P<
.20). However, in this group, also including low-grade
osteosarcomas,theangiogenesis,proliferationrateandindex
showed a tendency toward lower values (5.94, 43.2%, and
1565, resp.), whereas the p53 expression and p53 index
showed a tendency toward higher values (74.17 and 3277,
resp.). The elevated p53 scores were speciﬁcally caused by
extremely high values of this parameter in a few round cell
osteosarcomas included in this limited group of patients.
Dataonangiogenesisinbothpretreatmentandposttreat-
ment histological specimens were available in 25 patients,
and no statistically signiﬁcant diﬀerence in the degree of
microvascularity was disclosed in the two series of biopsies
(P = .64). Analyses among the other quantitative variables
investigated showed mostly no statistically signiﬁcant asso-
ciations (P>. 10), apart from various associations between
estimates of proliferation and the p53 expression in the stud-
ied osteosarcomas. Thus, estimates of the pre-chemotherapy
p53 expression were inversely associated with both pre- and
post-chemotherapy estimates of proliferation (P<. 04). On
the other hand, estimates of the post-chemotherapy p53
expression were positive associated with the same estimates
of tumor cell proliferation (P<. 02). These associations,
however, also are reﬂections of the decreased proliferation
in post-chemotherapy osteosarcomas (Table 4), which was
statistically signiﬁcant regarding estimates of proliferation
index (P = .02). No associations were detected between
the quantitative variables and the largest tumor diameter
(P>. 12) or clinical parameters (P>. 10).
5.3. MDR/P-glycoprotein
A total of 60 primary, diagnostic biopsies (52%) showed a
Pgpscorelessthan2,and56biopsies(48%)expressedascore
higher than 2, whereas one biopsy could not be evaluated.
In the group of nonconventional osteosarcomas, the cases
considered to be chemotherapy sensitive constituted 63% of
thecases.ThePgpexpressionshowednocorrelationwiththe
investigated quantitative and semiquantitative parameters
(angiogenesis, P>. 15; proliferation rate, P>. 54; pro
liferation index, P>. 51; p53 expression, P>. 13; p53 index,
P>. 22).
Six out of 46 osteosarcomas were associated with 100%,
chemotherapeutically induced tumor necrosis, and in 3 cases
the post-chemotherapy specimens could not be immuno-
histochemically evaluated. In the former 6 osteosarcomas,
the corresponding Pgp expression in the pre-chemotherapy,Flemming Brandt Sorensen et al. 7
Table 4: The relationships between estimates of tumor cell proliferation and nuclear p53 expression in 46 osteosarcomas, before and after
preoperative chemotherapy.
Pre-chemotherapy Post-chemotherapy
N Mean N Mean P value
a
Proliferation rate (%) 46 54.48 39b 42.8 .86
Proliferation index (mm−2)
c 46 2230 39b 1327 .02
p53 expression (%) 46 61.0 39b 64.8 .85
p53 index (mm−2)
c 46 2573 39b 2190 .32
aStudent’s unpaired t-test.
bOne case could not be evaluated, whereas 6 cases were associated with 100% tumor necrosis.
cIndex reﬂects the number of positive nuclear proﬁles pr. mm2 tissue.
Table 5: Multiple drug resistance (Pgp expression) in 37 osteosar-
comas in pre- and post-chemotherapy biopsies, respectively
a. P
value
c = .10.
Pre-chemotherapy
MDR-scoreb
Post-chemotherapy MDR-scoreb 
<2 ≥2
<2 20 1 21
≥2 51 1 1 6

25 12 37
aT h r e ec a s e sc o u l dn o tb ee v a l u a t e di nt h ep o s t - c h e m o t h e r a p ys p e c i m e n s ,
and 6 cases were associated with 100% tumor necrosis.
bMDR-score ≥2 indicates resistance to chemotherapy.
cMcNemar’s test.
Table 6: Relationships between multiple drug resistance (Pgp
expression) in pre-chemotherapy biopsies of 46 osteosarcomas and
histological response (necrosis) in surgical specimens
a. Pv a l u e
b =
.53.
Pre-chemotherapy MDR-scorea Tumor necrosis 
<90% ≥90%
≥21 2 7 1 9
<21 6 1 1 2 7

28 18 46
aMDR-score ≥2 indicates resistance to chemotherapy.
bFisher’s exact test.
diagnostic biopsies showed a score of 1 (i.e., chemotherapy
sensitivity) in 4 cases, score 2 (chemotherapy resistance) in
one case, and for the remaining case the pretreatment biopsy
could not be evaluated for technical reasons.
Inthe37osteosarcomas,wherepost-chemotherapybiop-
sieswereavailable,therewasnostatisticallysigniﬁcantdiﬀer-
ence in Pgp expression in the pre- and post-chemotherapy
biopsies, respectively (P = .10), although the MDR-score
changed from resistance to chemotherapy sensitive status
in 4 cases (Table 5). High values of the MDR-score in the
pre-chemotherapy biopsies were positively correlated with
high values of the same parameter in the paired, post-
chemotherapy tumor specimens (P = .003). Moreover, the
expression of Pgp in the primary, diagnostic biopsies was not
predictive of the degree of chemotherapy-induced tumor cell
necrosis (P = .53; Table 6).
5.4. Prognosticevaluation
The overall disease-speciﬁc survival in the entire series of
patient, from inclusion to closure of the study period, was
50%, with the group of patients receiving chemotherapy
showing a survival of 54%, and in the cohort of patients
prior to the era of chemotherapy the overall survival was
47%. Regarding recurrence-free survival, the same ﬁgures
were 48%, 53%, and 45%, respectively. The group of
patients with nonconventional osteosarcomas showed no
statistical diﬀerences regarding the quantitative variables
investigated, when compared to the whole series of patients
investigated (.06 <P<. 20), and accordingly, patients with
all morphological tumor types were aggregated into one
prognostic analysis. Moreover, separate statistical analysis
of patients treated before or after the introduction of
chemotherapy showed no individual diﬀerences for the
investigated quantitative variables. Accordingly, the results of
the prognostic evaluation are presented for the whole series
of patients.
Patient sex, tumor site and extent, diagnostic delay, and
type of surgical treatment were without prognostic impact,
whereas patient age and histological type of osteosarcoma
showed prognostic value regarding survival (Table 7; Figures
4(b), 4(d)). Thus, high-grade osteosarcomas and age > 25
years were associated with poorer survival. Large tumor
diameter may carry a tendency to shorter survival, however,
nonsigniﬁcant (Table 7; Figure 4(c)). Interestingly, neither
the administration of preoperative chemotherapy nor the
histological response to chemotherapy (i.e., the extent of
tumor necrosis) provided any prognostic impact (Table 7).
The data obtained regarding angiogenesis, proliferation
rateandindex,p53expressionandindex,andPgpexpression
(Table 8 and Figure 4(a)) were without any prognostic value,
neither regarding patient survival (P>. 12) nor recurrence
of osteosarcoma (P>. 11).
6. DISCUSSION
Among the traditional clinicopathological variables, only the
type of osteosarcoma and patient age showed prognostic
impact regarding survival which is in agreement with other
studies of patients with conventional high-grade sarcomas
[1, 2, 5], but in contrast to earlier investigations. The size
[2, 4, 5, 7] of the tumor, patient sex [7], and diagnostic delay8 Sarcoma
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Figure 4: Kaplan-Meier plots of survival in patients with osteosarcoma regarding (a) multiple drug resistance score (P = .12; log rank test),
(b) histological type of osteosarcoma (P = .02), (c) tumor diameter (P = .11), (d) and patient age at diagnosis (P = .03).
[1, 2, 7] were nonsigniﬁcant regarding prognostic power.
In this study, older age, surgical treatment by amputation,
no surgical treatment and conventional high-grade osteosar-
coma were indicative of an unfavorable prognosis. This may
beareﬂectionofthecharacteristicsofthedatabaseinthatthe
patients have been collected over a period of about 30 years.
Moreover, the group of nonconventional osteosarcomas also
contained tumors of lower-grade malignancy.
On the other hand, it is surprising that neither pre-
operative chemotherapy nor histologic response to that
treatment showed prognostic impact. These results disagree
with most large studies of patients treated by preoperative
chemotherapy for osteosarcoma [3, 4, 6, 7], except for a
recent randomized phase III study by the European Osteosar-
coma Intergroup [19]. The latter multicenter investigation
could not document any relationship between the degree of
histologic response to chemotherapy and patient outcome
regarding survival [19]. The results of our study may reﬂect
matters of secularity related to the database investigated
in that the rarity of osteosarcoma necessitate collecting
patients for study over decades, a time frame within which
minor or even major changes in treatment may occur. An
overall, disease-speciﬁc patient survival of 47% before the
introduction of preoperative chemotherapy is rather high,
when compared to earlier studies [1, 2], and considering the
verylongfollow-uppresentedinthepresentstudy.Withsuch
a high survival rate before the introduction of preoperative
chemotherapy, the true value of the treatment may not
penetrate from the statistical analysis. One has, however,
to consider the retrospective design of the present study,
which also implies possible bias due to patient selection and
data confounding, especially related to treatment variables.Flemming Brandt Sorensen et al. 9
Table 7: Analyses of prognostic impact of clinicopathological,
categorical variables, grouped as shown in Table 1.
Survival
a Recurrence
b
Number of patients 116c 107d
P-values
e P-values
e
Sex .16 .33
Age
f .03 .79
Extent of tumor .91 .90
Type of osteosarcoma .02 .06
Largest tumor diameter
f .11 .36
Diagnostic delay
f .30 .13
Type of surgical treatment .16 .05
Preoperative chemotherapy .78 .31
Histological response to chemotherapy
g .33 .48
aSurvival analysis based on disease-speciﬁc mortality.
bAll kinds of recurrences, but patients with persistent, progressive disease
after primary therapy have been deleted from the analyses.
cOne patient, who did not receive preoperative chemotherapy, died from
unrelated disease, and has been censored from the statistical analysis.
dSix and 4 patients, who did not or did receive preoperative chemotherapy,
respectively, had persistent, progressive disease after primary treatment, and
are excluded from the statistical analysis.
eP- v a l u e sa sr e p o r t e df r o ml o g - r a n kt e s t s .
fAnalysis based on a 3-group comparison, divided on the tertiles.
gAnalysis based on a comparison between patients (showing ≥90% versus
<90% tumor necrosis, resp.).
Nevertheless, the beneﬁt of chemotherapy was reﬂected by
the shift from domination of amputation to preferential
limb-sparing and wide surgical resection before and after the
introduction of chemotherapy, respectively.
The fraction of proliferating tumor cells in the inves-
tigated series of osteosarcomas ranged from 5% through
90%. This represents a larger range than that obtained in
some studies [10, 24–26], but corresponds to the ﬁgures
reported by German investigators [27, 28]. We used the
TSA technique to improve the often rather weak immuno-
histological staining for MIB-1, which may explain our
higher range of osteosarcoma cells in proliferation cycle.
The discrepancies may, however, also be caused by a
large number of confounding parameters, associated with
the diﬀerent immunohistological techniques and antigen
retrieval methods, and dealing with retrospective, paraﬃn-
embedded archival tissue, that is, the standardization of
ﬁxation methods is questionable. Furthermore, it has been
shown that the Ki-67/MIB-1 antibody may stain noncycling
cells that overexpress p53 [29], which may indeed be the case
in osteosarcomas [26].
There was no signiﬁcant reduction in the proliferation
rate in post-chemotherapy specimens, but a statistically
signiﬁcant decrease in the proliferation index was demon-
strated. This is, however, just a reﬂection of the used
arithmetic, in that the proliferation index is related to the
area of tissue investigated, and not the number of MIB-1
negative cells, and the area without tumor cells increases
when chemotherapy makes its eﬀect.
It has been suggested that MIB-1 could be used as
an adjuvant variable in the morphological classiﬁcation of
primary bone tumorsbecauselow-grade osteosarcomashave
been shown to have a lower proliferation rate than conven-
tional high-grade sarcomas [24], and low-grade osteosarco-
mas have a higher MIB-1 rate than ﬁbrous dysplasia [30].
With the problems associated with immunohistochemical
techniques, mentioned above, and our ﬁnding of non-
signiﬁcant, lower values of MIB-1 rate in nonconventional
osteosarcomas, we would advise against employing MIB-1
estimates for guidance in classiﬁcation of osteosarcomas.
An increased rate of proliferation in metastases, when
compared with the MIB-1 rate in the corresponding primary
osteosarcomas, has been published [31], and thus adds
evidence to the suggested role of MIB-1 rate to act as
an indicator of biological behavior of osteosarcomas [25].
Prognostic impact of the proliferation rate has been reported
in patients with both skeletal [32, 33]a n de x t r a s k e l e t a l[ 34]
osteosarcomas, in contrast to our ﬁndings, which, however,
are corroborated by other investigators [10, 26].
Most studies addressing the immunohistochemical
expression of p53 in osteosarcomas have used a semiquan-
titative scoring approach of the staining results [35–40],
often with a 10% or 20% threshold for scoring a tumor
as p53 positive. Using this approach, the immunoreactivity
for p53 has been used in attempts to classify bone tumors
[39, 41]. We have used a strictly quantitative, morphometric
technique, in accordance with an earlier editorial on this
issue [42], which explains a frequency of 100% of p53
positivity in our series of osteosarcomas. The staining
pattern, and thus the diﬀerence in p53 reactivity, was highly
diﬀerent among individual tumors, showing a range from
5%through100%p53-positivetumorcells.Ourreservations
in interpreting the immunohistochemical results for MIB-1
are, however, also valid for p53. In addition, we experienced
a rather dramatic heterogeneity in p53 staining within the
same slide from one tumor, and will accordingly recommend
a random-systematic sampling approach in immunohis-
tochemical studies of immunohistochemical cellular p53-
expression.
In accordance with our results, immunohistochemical
investigations of p53 in patients with osteosarcomas have
not demonstrated prognostic impact [26, 31, 43]. Changed
p53 protein expression may not convey mutation in the
P53 gene [36], and accordingly, genetic studies of P53 gene
alteration may be of value. However, a few studies based
on molecular technology in evaluating the P53 gene in
osteosarcomas have not been able to document prognostic
value in osteosarcomas [11, 44, 45]. Nevertheless, it may,
from the theoretical point of view, still be valuable to
study various suppressor genes like P53 and their protein
expressions, in that osteosarcomas are known to occur
with higher frequency in persons with impaired or defect
suppressor genes like in the case of inherited retinoblastoma
[46, 47]. Indeed, a recent study has shown prognostic impact
ofthecombinedinformationregardingproteinexpressionof
markers of apoptotic cell death, such as p53, bax, and bcl-2,
ascomparedtomissingprognosticvaluedisplayedbyeachof
these molecules individually [48]. Also, the combination of
p53 with information regarding Pgp has been documented
to contain stronger prognostic information than the two10 Sarcoma
Table 8: Analyses of prognostic impact of quantitative and semiquantitative immunohistological estimates, as obtained from the
pretreatment biopsies (number of patients analyzed shown in brackets).
Survival
a Recurrence
b
no pre-chemotherapy +pre-chemotherapy no pre-chemotherapy +pre-chemotherapy
P-values
c P-values
c
Angiogenesis
d .90 .92 .23 .76
(65) (30) (65) (35)
Proliferation rate (%) .56 .52 .82 .54
(70) (46) (65) (42)
Proliferation index (mm−2) .47 .81 .43 .89
(70) (46) (65) (42)
p53 expression (%) .18 .29 .43 .11
(70) (46) (65) (42)
p53 index (mm−2) .73 .99 .90 .90
(70) (46) (65) (42)
MDR/Pgp .43 .12 .23 .16
(70) (46) (65) (42)
aAnalysis based on disease-speciﬁc mortality, and for continuous parameters divided on the median, whereas for MDR/Pgp divided in a chemotherapy-
sensitive group (score <2) and a chemotherapy-resistant group (score ≥2).
bAll kinds of recurrences, but patients with persistent, progressive disease after primary therapy have been deleted from the analyses.
cP- v a l u e sa sr e p o r t e df r o ml o g - r a n kt e s t s .
dAngiogenesis could not be estimated in 21 cases due to technical, immunohistological problems, see text.
variables separately [49]. Thus, the true prognostic value
of p53/ P53 on either the protein or gene expression level,
respectively, awaits further clariﬁcation.
The rate of Pgp positive osteosarcomas in the present
investigation was comparable to ﬁndings in other stud-
ies [50–52], but on the average, often a little higher
than reported by other investigators [12, 53, 54]. Again,
these discrepancies can be caused by diﬀering techniques
employed, and may not reﬂect diﬀerences related per se
to the patient populations studied. Missing correlations
between Pgp expression and the level of proliferation and
p53 expression are in agreement with earlier ﬁndings [55].
Although showing a tight correlation, the Pgp expression
was not diﬀerent in primary, diagnostic biopsies and post-
chemotherapy specimens in the present series of patients
with osteosarcomas, and the Pgp level in the primary biopsy
could not predict the extent of chemotherapy-induced
necrosis. The latter ﬁndings have been reported by other
investigators [12, 51, 52], and a meta-analysis including
631 patients has conﬁrmed the missing predictive power of
Pgp expression with regard to the extent of chemotherapy-
induced tumor necrosis [56]. Our methodological approach
cannot, however, provide reliable answers to whether Pgp
expression is an accurate measure to predict chemotherapy
resistance, in that tumor cell necrosis in itself may not be an
accurate measure for this resistance.
The incidence of Pgp overexpression has been shown
to increase after chemotherapy [52], but our ﬁndings
cannot be compared reliably with this study, in that the
two investigations use quite diﬀerent scoring schemes for
evaluating the MDR-status. Although the incidence of Pgp
expression has been shown to be increased in metastatic
as compared to the corresponding primary osteosarcomas
[53, 54], this does probably not imply the development of
a more aggressive phenotype [57], and experimental data
suggest that MDR is not upregulated in the course of tumor
progression [58].
The prognostic impact of MDR/Pgp expression in
osteosarcomas is highly debatable. Some studies have shown
Pgp overexpression in primary, diagnostics biopsies to be
predictive of poor prognosis [12, 50, 53, 59], which may
be of relevance in planning the chemotherapy [60]. Other
authors have not been able to detect prognostic value of the
Pgp expression, as determined by immunohistochemistry
[40, 61]. Some of the confusion may be related to diﬀerences
in documenting and scoring immunohistochemical Pgp
expression. We have employed the international recommen-
dationofusingcocktailsoftwoormorevendor-standardized
anti-Pgp antibody reagents that recognize diﬀerent epitopes
[20]. This may improve the reliability of the immunohisto-
chemical, overall detection of Pgp, but the maybe unique
clinical or prognostic impact of the individual antibody
clones used remains undetected by our approach.
The immunohistochemical overexpression of Pgp may
not, however, reﬂect true genetic ampliﬁcation of the MDR-
gene [62], and quantitative RT-PCR analysis of osteosarco-
mas from 123 patients was unable to demonstrate any rela-
tionship between the genetic MDR expression and prognosis
[63].Sofaritseemsthatmostinvestigations,usingimmuno-
histochemical study design, favor prognostic signiﬁcance of
Pgpoverexpression,whichalsoistheconclusionofthemeta-
analyses mentioned above [56].
Investigations of angiogenesis in human osteosarcomas
are rather sparse, but some studies have shown prognostic
impact of estimates of angiogenesis, either directly [15–
17] or indirectly [64, 65], whereas others have not beenFlemming Brandt Sorensen et al. 11
able to prove any prognostic value by angioenesis [18].
Some research based on animal models suggests, however,
a role for angiogenesis in the evaluation of progression of
osteosarcoma [66], or in the treatment of such tumors with
antiangiogenetic drugs [67, 68]. We could not demonstrate
any prognostic impact by angiogenesis, and were unable to
ﬁnd any signiﬁcant diﬀerences in the degree of vascularity
in pre- and post-chemotherapy tumor specimens. Moreover,
there seems to be no obvious relationship between the grade
of angiogenesis and the expression of Pgp in individual
osteosarcomas, pointing to the conclusion that angiogenesis
is not associated with the accessibility of chemotherapeutics
to the vascular bed of the tumor cells. Only a nonsigniﬁcant
tendency to lower estimates of angiogenesis in nonconven-
tional osteosarcomas was revealed.
We have used the Chalkley technique [22], as recom-
mended by Vermeulen et al. [23], whereas other studies [14–
18, 64] on human osteosarcomas have used the microvessel
density score for estimating the grade of vascularity within
tumors investigated. Although estimates of angiogenesis
obtained by these two diﬀerent approaches may be corre-
lated, a direct comparison is not possible. The sampling
approach for both techniques is based on estimation within
preselected hot spots. Dealing with the highly heteroge-
neous vascular morphology in osteosarcomas, this sampling
method seems rational. Optimal sampling schemes, like ran-
dom systematic sampling, as used for scoring of proliferative
a c t i v i t ya n dp 5 3 - e x p r e s s i o n ,s e e m e di no u rh a n d su n s u i t e d
for angiogenesis estimation. Necrosis, condroblastic, and
bony-diﬀerentiated areas within the often small diagnostic
biopsies from osteosarcomas, as related to the focality of
neovascularisation (see Figure 2(a)), made such stereological
approach for estimating architectural structures like vessels
futile, in contrast to the suitability of this methodology in
quantifying cellular events like p53-expression and prolifera-
tion.
Furthermore, in our investigation, we have experienced
great diﬃculties in the immunohistological staining by anti-
bodies to CD34, reducing the number of cases available for
statistical analysis regarding patient survival and recurrence
of osteosarcoma. In our preliminary investigations, we also
tested out the usability of CD31 for immunohistochemical
detection of neoangiogenesis. However, CD31 showed an
immense, nonspeciﬁc background staining in the decalciﬁed
tissue sections, making it impossible to obtain reliably
quantitative estimates of angiogenesis.
Also, the end points for various analyses regarding
prognostic impact of angiogenesis are varying, in that
some studies focus on survival and recurrences, whereas
others primarily are addressing the response to preop-
erative chemotherapy, another point disabling bona ﬁde
comparisons between various investigations. Moreover, the
number of cases in the studies, published so far, is rather
sparse. Adding together all these problems associated with
estimation of neovascularity in osteosarcomas, we believe it
is too early to dismiss angiogenesis as a possible parameter
for prognostic evaluation, and for purposes of planning
treatment in the event antiangiogenetic drugs are introduced
in treatment trials of patients with osteosarcomas.
In searching for new morphologic and molecular predic-
tors of prognosis and treatment outcome, the oncopatholo-
gist is faced with the ﬁght against tumor heterogeneity [69].
Indeed, this battle seems insurmountable if one considers
the sparseness of the primary, diagnostic biopsy from the
mostlybulkyosteosarcomas.Theintratumoralheterogeneity
may be attributed to intrinsic, tumor cell-speciﬁc character-
istics or caused by the environment of the tumor growth.
Moreover, the tissue sampling within the tumors and the
technical approach used makes heterogeneity one of the
most diﬃcult obstacles to manage in both a scientiﬁc and
clinical contexts, even in the case of monomorphic, small
cell malignancies like, for example, Ewing sarcoma [70]. The
diagnosticbiopsyfromanosteosarcomawillalwaysrepresent
a keyhole of the neoplastic reality. Dealing with cellular
events like p53 expression and proliferative activity, system-
atic random sampling can combat some of the problems
relatedtoheterogeneity.Angiogenesisismorediﬃcultinthis
regard, and a semiquantitative approach seems most feasible
for quantifying such architectural aspects. Monitoring the
expression of MDR/Pgp is also highly sensitive to tumor het-
erogeneity, but one molecular study, aimed at this particular
issue, has revealed very little variation of intratumoral MDR
expression [71]. The overall impact of all these problems
suggests humbleness in interpreting, and in taking clinical
consequence of studies of prognostic variables in all kinds
of human neoplasms.
7. CONCLUSION
This retrospective, immunohistochemical study of patients
treatedforosteosarcomadoesnotdiscloseprognosticimpact
of quantitative estimates regarding angiogenesis, tumor cell
proliferation, p53 status, or P-glycoprotein expression. Like-
wise, the use of preoperative chemotherapy and the extent of
induced tumor cell necrosis were without prognostic value.
Although the study has a retrospective design which may
inﬂictdataconfoundingandbias,theseﬁndingsmaybeasso-
ciated to the fact that the overall survival was around 50%
even before the introduction of preoperative chemotherapy.
Conﬂicting evidence in the literature regarding the true,
prognostic impact of the dogmatized, predictive value of the
histopathologic response to preoperative chemotherapy in
patients suﬀering from osteosarcoma may ask for intensiﬁed
research regarding the pretreatment, predictive value of, for
example, patient-speciﬁc qualities like MDR status.
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